Metastatic Breast Cancer Clinical Trials

A listing of 68 Metastatic Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Breast Cancer

25 - 36 of 68

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 68 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Metastatic Breast Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

NCT05596409

Recruiting

The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) advanced/metastatic breast cancer who received no prior cyclin-dependent kinase targeting enzymes CDK4 and CDK6 inhibitor (CDK4/6i) in the metastatic setting.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/25/2025

Locations: Highlands Oncology Group, PA, Springdale, Arkansas +33 locations

Highlands Oncology Group, PA, Springdale, Arkansas

OPN Healthcare, Arcadia, California

University of Colorado Cancer Center, Aurora, Colorado

Morton Plant Hospital - Baycare Health System, Clearwater, Florida

Northwestern University, Northwestern Feinberg School of Medicine Prentice Women's Hospital, Chicago, Illinois

Inventa Center for Cancer Research at Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

Alliance for Multispecialty Research, Merriam, Kansas

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

The Toledo Clinic, Toledo, Ohio

UT Health San Antonio Mays Cancer Center, San Antonio, Texas

Quality Cancer Care Alliance (QCCA) Northwest Medical Specialties, Tacoma, Washington

Centro de Pesquisas Clinicas em Oncologia (Center for Clinical Research in Oncology (CPCO)) - Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro De Itapemirim, Espirito Santo

Hospital São Lucas PUCRS - Centro de Pesquisa em Oncologia (CPO), Porto Alegre, Rio Granda Do Sul

Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Granda Do Sul

Centro de Pesquisas Oncologicas, Florianópolis, Santa Catarina

Hospital de Amor de Barretos, Barretos, São Paulo

Centro de Estudos e Pesquisas de Hematologia e Oncologia- CEPHO, Santo Andre, São Paulo

Centro De Pesquisa Clinica DO Hospital Sirio-Libanes - UNIDADE Brasilia, Brasília, Not set

Clinica de Pesquisas e Centro de Estudos Em Oncologia Ginecologica e Mamaria Ltda, São Paulo, Not set

Complex Oncology Center, Plovdiv, Not set

COMPLEX ONCOLOGICAL CENTER - Shumen, Shumen, Not set

COC Veliko Tarnovo, Veliko Tarnovo, Not set

Cancer Research Centre, Tbilisi, Not set

Innova Medical Center, Tbilisi, Not set

LTD Simon Khechinashvili University Clinic, Tbilisi, Not set

Multiprofile Clinic Consilium Medulla, Tbilisi, Not set

Institute of Clinical Oncology, Tbilisi, Not set

Todua Clinic, Tbilisi, Not set

I CAN Oncology Center, Centro Medico AVE, Monterrey, Nuevo Leon

Torre Medica Hospital Dalinde, Ciudad de Mexico, Not set

Fucam, Ac., Ciudad de Mexico, Not set

Unidad Médica Onco-Hematológica, Puebla, Not set

Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj Napoca, Cluj Napoca, Cluj

Centrul de Oncologie "Sf. Nectarie", Craiova, Dolj

Conditions: Metastatic Breast Cancer

Learn More ›

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

NCT05846789

Recruiting

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana +3 locations

Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer

Learn More ›

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

NCT04115306

Recruiting

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/06/2025

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +7 locations

Conditions: Metastatic Breast Cancer

Learn More ›

Primary Breast Oligoprogressive Sites Treated with Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881

Recruiting

This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations

Conditions: Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC V8, Metastatic Breast Cancer

Learn More ›

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337

Recruiting

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Research Site 1141-0, Tucson, Arizona +184 locations

Research Site 1141-0, Tucson, Arizona

Research Site 1114-0, Fullerton, California

Research Site 1107-0, Los Angeles, California

Research Site 1118-0, Orange, California

Research Site 1143-0, Sacramento, California

Research Site 1132-0, Santa Barbara, California

Research Site 1129-0, Lone Tree, Colorado

Research Site 1125-0, Palm Bay, Florida

Research Site 1110-0, Savannah, Georgia

Research Site 1124-0, Chicago Ridge, Illinois

Research Site 1106-0, Merriam, Kansas

Research Site 1104-0, Louisville, Kentucky

Research Site 1122-0, Silver Spring, Maryland

Research Site 8639-0, Silver Spring, Maryland

Research Site 1109-0, Kansas City, Missouri

Research Site 1111-0, Florham Park, New Jersey

Research Site 1105-0, Westbury, New York

Research Site 1144-0, Chapel Hill, North Carolina

Research Site 1138-0, Akron, Ohio

Research Site 1133-0, Eugene, Oregon

Research Site 1126-0, Tigard, Oregon

Research Site 1134-0, Broomall, Pennsylvania

Research Site 1123-0, Horsham, Pennsylvania

Research Site 1149-0, Knoxville, Tennessee

Research Site 1102-0, Nashville, Tennessee

Research Site 1101-0, Dallas, Texas

Research Site 1116-0, Denison, Texas

Research Site 1115-0, Houston, Texas

Research Site 1117-0, San Antonio, Texas

Research Site 1130-0, Salt Lake City, Utah

Research Site 1108-0, Fairfax, Virginia

Research Site 1131-0, Fairfax, Virginia

Research Site 1127-0, Roanoke, Virginia

Research Site 5401-0, Rosario, Santa Fe

Research Site 5404-0, San Miguel de Tucuman, Tucuman

Research Site 6108-0, Camperdown, New South Wales

Research Site 6109-0, Liverpool, New South Wales

Research Site 6102-0, Sydney, New South Wales

Research Site 6106-0, Birtinya, Queensland

Research Site 6101-0, South Brisbane, Queensland

Research Site 6107-0, Southport, Queensland

Research Site 6104-0, Townsville, Queensland

Research Site 6110-0, Adelaide, South Australia

Research Site 6103-0, Bendigo, Victoria

Research Site 6105-0, St. Albans, Victoria

Research Site 3201-0, Brussels, Not set

Research Site 3204-0, Gent, Not set

Research Site 3205-0, Jette, Not set

Research Site 3203-0, Leuven, Not set

Research Site 3207-0, Liege, Not set

Research Site 3202-0, Roeselare, Not set

Research Site 1003-0, Brampton, Ontario

Research Site 1001-0, Toronto, Ontario

Research Site 1004-0, Montreal, Quebec

Research Site 1005-0, Montreal, Quebec

Research Site 1006-0, Montreal, Quebec

Research Site 1002-0, Sherbrooke, Quebec

Research Site 8640-0, Hefei, Anhui

Research Site 8614-0, Hefei, Anhui

Research Site 8601-0, Beijing, Beijing

Research Site 8625-0, Beijing, Beijing

Research Site 8627-0, Chongqing, Chongqing

Research Site 8651-0, Fuzhou, Fujian

Research Site 8638-0, Xiamen, Fujian

Research Site 8630-0, Lanzhou, Gansu

Research Site 8604-0, Guangzhou, Guangdong

Research Site 8628-0, Guangzhou, Guangdong

Research Site 8621-0, Huizhou, Guangdong

Research Site 8622-0, Zhuhai, Guangdong

Research Site 8615-0, Nanning, Guangxi

Research Site, Baoding, Hebei

Research Site 8629-0, Baoding, Hebei

Research Site 8645-0, Shijiazhuang, Hebei

Research Site 8619-0, Harbin, Heilongjiang

Research Site 8649-0, Anyang, Henan

Research Site 8609-0, Luoyang, Henan

Research Site 8648-0, Weihui, Henan

Research Site 8605-0, Zhengzhou, Henan

Research Site 8623-0, Zhengzhou, Henan

Research Site 8637-0, Wuhan, Hubei

Research Site 8608-0, Wuhan, Hubei

Research Site 8633-0, Xiangyang, Hubei

Research Site 8635-0, Changsha, Hunan

Research Site 8654-0, Yongzhou, Hunan

Research Site 8646-0, Huai'an, Jiangsu

Research Site 8607-0, Nanjing, Jiangsu

Research Site 8624-0, Xuzhou, Jiangsu

Research Site 8631-0, Nanchang, Jiangxi

Research Site 8612-0, Changchun, Jilin

Research Site 8618-0, Changchun, Jilin

Research Site 8644-0, Changchun, Jilin

Research Site 8636-0, Dalian, Liaoning

Research Site-8636-0, Dalian, Liaoning

Research Site 8643-0, Shenyang, Liaoning

Research Site 8642-0, Shenyang, Liaoning

Research Site 8634-0, Jinan, Shandong

Research Site 8613-0, Jining, Shandong

Research Site 8610-0, Linyi, Shandong

Research Site 8650-0, Weihai, Shandong

Research Site 8603-0, Shanghai, Shanghai

Research Site 8602-0, Shanghai, Shanghai

Research Site 8611-0, Xi'an, Shanxi

Research Site 8606-0, Chengdu, Sichuan

Research Site 8626-0, Neijiang, Sichuan

Research Site 8647-0, Zigong, Sichuan

Research Site 8617-0, Tianjin, Tianjin

Research Site 8616-0, Urumqi, Xinjiang

Research Site 8632-0, Kunming, Yunnan

Research Site 8652-0, Hangzhou, Zhejiang

Research Site 8620-0, Hangzhou, Zhejiang

Research Site 8641-0, Hangzhou, Zhejiang

Research Site 3311-0, Marseille cedex 20, Bouches-du-Rhône

Research Site 3303-0, La Rochelle cedex, Charente Maritime

Research Site 3312-0, Besancon Cedex, Doubs

Research Site 3308-0, Nimes, Gard

Research Site 3314-0, Bordeaux, Gironde

Research Site 3305-0, Toulouse cedex 09, Haute Garonne

Research Site 3309-0, Limoges, Haute Vienne

Research Site 3304-0, Montpellier, Herault

Research Site 3310-0, Saint Herblain, Loire Atlantique

Research Site 3301-0, Angers Cedex 2, Maine Et Loire

Research Site 3315-0, Lille cedex, Nord

Research Site 3306-0, Bayonne cedex, Pyrenees Atlantiques

Research Site 3318-0, Pierre Benite cedex, Rhone

Research Site 3313-0, Rouen, Seine Maritime

Research Site 3307-0, Avignon Cedex 9, Vaculuse

Research Site 3302-0, Creteil Cedex, Val De Marne

Research Site 3316-0, Paris, Not set

Research Site 4904-0, Bottrop, Nordrhein Westfalen

Research Site 8501-0, Hong Kong, Not set

Research Site 8503-0, Hong Kong, Not set

Research Site 8502-0, Hong Kong, Not set

Research Site 8505-0, Hong Kong, Not set

Research Site 3603-0, Budapest, Not set

Research Site 3606-0, Gyor, Not set

Research Site 3604-0, Kecskemet, Not set

Research Site 3602-0, Salgotarjan, Not set

Research Site 3607-0, Tatabanya, Not set

Research Site 9702-0, Jerusalem, Not set

Research Site 9703-0, Kfar-Saba, Not set

Research Site 9704-0, Petach-Tikva, Not set

Research Site 9705-0, Rehovot, Not set

Research Site 3908-0, Bergamo, Not set

Research Site 3907-0, Brescia, Not set

Research Site 3901-0, Catania, Not set

Research Site 3903-0, Catanzaro, Not set

Research Site 3906-0, Milano, Not set

Research Site 3911-0, Milano, Not set

Research Site 3904-0, Milano, Not set

Research Site 3909-0, Napoli, Not set

Research Site 3905-0, Verona, Not set

Research Site 8211-0, Wonju, Gangwon-do

Research Site 8204-0, Seongnam, Gyeonggi-do

Research Site 8201-0, Seoul, Gyeonggi-do

Research Site 8202-0, Suwon, Gyeonggi-do

Research Site 8208-0, Busan, Not set

Research Site 8209-0, Incheon, Not set

Research Site 8207-0, Seoul, Not set

Research Site 8206-0, Seoul, Not set

Research Site 8210-0, Seoul, Not set

Research Site 8203-0, Seoul, Not set

Research Site 8205-0, Seoul, Not set

Research Site 4802-0, Rzeszów, Not set

Research Site 4807-0, Torun, Not set

Research Site 4803-0, Łódź, Not set

Research Site 3403-0, Sant Cugat del Valles, Barcelona

Research Site 3409-0, Santiago de Compostela, La Coruña

Research Site 3406-0, Majadahonda, Madrid

Research Site 3410-0, Barcelona, Not set

Research Site 3402-0, Barcelona, Not set

Research Site 3404-0, Barcelona, Not set

Research Site 3416-0, Madrid, Not set

Research Site 3407-0, Madrid, Not set

Research Site 3414-0, Madrid, Not set

Research Site 3401-0, Madrid, Not set

Research Site 3415-0, Málaga, Not set

Research Site 3408-0, Sevilla, Not set

Research Site 3413-0, Sevilla, Not set

Research Site 3412-0, Valencia, Not set

Research Site 4404-0, Truro, Cornwall

Research Site 4408-0, London, Greater London

Research Site 4409-0, London, Greater London

Research Site 4402-0, Manchester, Greater Manchester

Research Site 4407-0, Leeds, West Yorkshire

Research Site 4401-0, Nottingham, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

NCT06855654

Recruiting

This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervention, overall and stratified by race, and to evaluate the feasibility and acceptability of the PRISM intervention in the MBC population. Black women with MBC have shorter survival from the time of meta... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: The University of Alabama, Birmingham, Alabama +1 locations

Conditions: Breast Cancer, Metastatic Breast Cancer

Learn More ›

The COMPASSION Study

NCT06507930

Recruiting

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/25/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts

Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Breast Carcinoma

Learn More ›

Phase II Single Arm Trial of Low Dose Capecitabine in Patients with Advanced Breast Cancer

NCT06105684

Recruiting

This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a greater risk of complications and poorer outcomes with other treatments.

Gender:

FEMALE

Ages:

60 years and above

Trial Updated:

02/23/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama

Conditions: Metastatic Breast Cancer

Learn More ›

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126

Recruiting

The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: Yale School of Medicine, New Haven, Connecticut +13 locations

Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

Learn More ›

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337

Recruiting

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: Natera, Inc. (Data and Specimen Analysis Only), San Carlos, California +11 locations

Conditions: Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma

Learn More ›

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

NCT04990921

Recruiting

This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: James Graham Brown Cancer Center, Louisville, Kentucky

Conditions: Metastatic Breast Cancer

Learn More ›

TReatment of ADC-Refractory Breast CancEr with Dato-DXd or T-DXd: TRADE DXd

NCT06533826

Recruiting

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-low metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/12/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer

Learn More ›

25 - 36 of 68